Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 41

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 3
Chunk 41
---
 a reduction in the market
price of our ordinary shares or ADSs.

24

As of March 16, 2025, as a result of previous financings, we had
(A) warrants outstanding (i) for the purchase of 1,596 ADSs at an exercise price of $564.00 per ADS, (ii) for the purchase of 17,969 ADSs
at an exercise price of $120.00 per ADS, (iii) for the purchase for the purchase of 277,273 ADSs at an exercise price of $46.00 per ADS,
(iv) for the purchase of 17,045 ADSs at an exercise price of $55.00 per ADS, (v) for the purchase of 187,500 ADSs at an exercise price
of $32.00 per ADS, (vi) for the purchase of 205,893 ADSs at an exercise price of $23.60 per ADS and (vii) for the purchase of 1,250,000
ADSs at an exercise price of $8.00 per ADS and (viii) for the purchase of 62,500 ADSs at an exercise price of $10.00 per ADS and (B) pre-funded
warrants outstanding for the purchase of 82,357 ADSs at an exercise price of $0.004 per ADS.

On September 3, 2021, we entered into an offering agreement, or
the HCW Offering Agreement, with H. C. Wainwright & Co., LLC, or HCW, pursuant to which we may offer and sell, at our option, up to
$25.0 million of our ADSs through an “at-the-market” equity program under which HCW agreed to act as sales agent. As of March
16, 2025, we have sold 194,656 of our ADSs for total gross proceeds of approximately $6.0 million under the New HCW Offering Agreement.

As of March 16, 2025, in the framework of our Share Incentive Plan, there are outstanding
options, restricted share units and performance share units (granted to directors, employees and consultants) for the purchase of 131,167,200
ordinary shares (equivalent to 218,612 ADSs) with a weighted average exercise price of $0.10 per ordinary share (equivalent to $58.85
per ADS).

The issuance of any additional ordinary shares, any additional